Amicus Therapeutics, Inc. (FOLD)
|52 Week Range||9.7-14.1|
|1y Target Est||-|
|DCF Unlevered||FOLD DCF ->|
|DCF Levered||FOLD LDCF ->|
|Debt / Equity||340.96%||Strong Buy|
Upgrades & Downgrades
Latest FOLD news
Amicus' (FOLD) Q3 Loss Narrows, Galafold Sales View Updated
9 November 2023
Amicus (FOLD) incurs a narrower-than-expected loss in the third quarter. However, revenues beat estimates.
Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2023
1 November 2023
PRINCETON, N.J., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences i...
Amicus Therapeutics: The Right Play Now
31 October 2023
Amicus Therapeutics, Inc. is a commercial-stage biotech company focused on developing therapies for rare diseases. The company recently received FDA approval for its combination therapy Pombiliti + Op...
Amicus Therapeutics to Announce Third Quarter 2023 Financial Results on November 8, 2023
27 October 2023
PRINCETON, N.J., Oct. 27, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Wednesday, November 8, 2023...
Amicus (FOLD) Gets FDA Approval for Pompe Disease Drug
29 September 2023
Amicus (FOLD) receives approval for Pombiliti (cipaglucosidase alfa) + Opfolda (miglustat) from the FDA to treat the adult late-onset Pompe disease.
3 Stocks Worth a Watch for Solid Earnings Acceleration
20 September 2023
Some of the notable companies to have witnessed solid earnings acceleration as of now are Amicus Therapeutics (FOLD), Genius Sports (GENI) and Viad (VVI).
Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2023
1 September 2023
PHILADELPHIA, Sept. 01, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in ...
FATE Q2 Earnings Beat on Lower Expenses, Revenues Miss
9 August 2023
FATE reports a lower-than-expected loss on a decline in operating expenses in the second quarter of 2023.
Amicus (FOLD) Misses on Q2 Earnings, Raises Revenue Guidance
9 August 2023
Amicus (FOLD) incurs wider-than-expected loss in the second quarter. Fabry disease drug Galafold reports encouraging revenues and the company raises its 2023 guidance for the same.